-
1.发明申请公开(公告)号：US20130064805A1
公开(公告)日：2013-03-14
申请号：US13667294
申请日：2012-11-02
发明人： Hitoshi Sakuraba , Youichi Tajima , Mai Ito , Seiichi Aikawa , Fumiko Aikawa
CPC分类号： C12N9/2465 , A61K38/00 , C12N9/2402 , C12Y302/01022 , C12Y302/01049
摘要： The present invention provides, as an enzyme which can be used for enzyme replacement therapy for Fabry disease, a protein having α-galactosidase activity, which shows no allergic adverse side effect, shows a high stability in blood, and can be easily incorporated into a cell of an affected organ. The protein of the present invention is a protein which has acquired α-galactosidase activity by changing the structure of the active site of wild-type human α-N-acetylgalactosaminidase.
摘要翻译： 本发明提供作为法布里病的酶替代疗法的酶，不具有过敏性副作用的具有α-半乳糖苷酶活性的蛋白质在血液中显示高稳定性，并且可以容易地加入到 受影响器官的细胞。 本发明的蛋白质是通过改变野生型人α-N-乙酰半乳糖胺酶活性位点的结构而获得α-半乳糖苷酶活性的蛋白质。
-
公开(公告)号：US08668907B2
公开(公告)日：2014-03-11
申请号：US13667294
申请日：2012-11-02
发明人： Hitoshi Sakuraba , Youichi Tajima , Mai Ito , Seiichi Aikawa , Fumiko Aikawa
CPC分类号： C12N9/2465 , A61K38/00 , C12N9/2402 , C12Y302/01022 , C12Y302/01049
摘要： The present invention provides, as an enzyme which can be used for enzyme replacement therapy for Fabry disease, a protein having α-galactosidase activity, which shows no allergic adverse side effect, shows a high stability in blood, and can be easily incorporated into a cell of an affected organ. The protein of the present invention is a protein which has acquired α-galactosidase activity by changing the structure of the active site of wild-type human α-N-acetylgalactosaminidase.
摘要翻译： 本发明提供作为可用于法布里病的酶替代疗法的酶，不具有过敏性副作用的具有α-半乳糖苷酶活性的蛋白质在血液中显示高稳定性，并且可以容易地并入 受影响器官的细胞。 本发明的蛋白质是通过改变野生型人α-N-乙酰半乳糖胺酶的活性位点的结构而获得α-半乳糖苷酶活性的蛋白质。
-
3.发明申请公开(公告)号：US20140171493A1
公开(公告)日：2014-06-19
申请号：US14162135
申请日：2014-01-23
发明人： Hitoshi Sakuraba , Youichi Tajima , Mai Ito , Seiichi Aikawa , Fumiko Aikawa
IPC分类号： C12N9/40
CPC分类号： C12N9/2465 , A61K38/00 , C12N9/2402 , C12Y302/01022 , C12Y302/01049
摘要： The present invention provides, as an enzyme which can be used for enzyme replacement therapy for Fabry disease, a protein having α-galactosidase activity, which shows no allergic adverse side effect, shows a high stability in blood, and can be easily incorporated into a cell of an affected organ. The protein of the present invention is a protein which has acquired α-galactosidase activity by changing the structure of the active site of wild-type human α-N-acetylgalactosaminidase.
摘要翻译： 本发明提供作为法布里病的酶替代疗法的酶，不具有过敏性副作用的具有α-半乳糖苷酶活性的蛋白质在血液中显示高稳定性，并且可以容易地加入到 受影响器官的细胞。 本发明的蛋白质是通过改变野生型人α-N-乙酰半乳糖胺酶活性位点的结构而获得α-半乳糖苷酶活性的蛋白质。
-
公开(公告)号：US09193964B2
公开(公告)日：2015-11-24
申请号：US14162135
申请日：2014-01-23
发明人： Hitoshi Sakuraba , Youichi Tajima , Mai Ito , Seiichi Aikawa , Fumiko Aikawa
IPC分类号： A61K48/00 , A61K38/47 , A61K38/43 , C12N9/40 , C12P21/06 , C12P19/34 , C12N15/00 , C07H21/04 , C07K1/00 , C12N9/24 , A61K38/00
CPC分类号： C12N9/2465 , A61K38/00 , C12N9/2402 , C12Y302/01022 , C12Y302/01049
摘要： The present invention provides, as an enzyme which can be used for enzyme replacement therapy for Fabry disease, a protein having α-galactosidase activity, which shows no allergic adverse side effect, shows a high stability in blood, and can be easily incorporated into a cell of an affected organ. The protein of the present invention is a protein which has acquired α-galactosidase activity by changing the structure of the active site of wild-type human α-N-acetylgalactosaminidase.
摘要翻译： 本发明提供作为法布里病的酶替代疗法的酶，不具有过敏性副作用的具有α-半乳糖苷酶活性的蛋白质在血液中显示高稳定性，并且可以容易地加入到 受影响器官的细胞。 本发明的蛋白质是通过改变野生型人α-N-乙酰半乳糖胺酶活性位点的结构而获得α-半乳糖苷酶活性的蛋白质。
-
-
-
搜索结果
4 条记录 (耗时 0.019 秒)
